EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations

A. Nast; C. Smith; P. I. Spuls; G. Avila Valle; Z. Bata-Csörgö; H. Boonen; E. de Jong; I. Garcia-Doval; P. Gisondi; D. Kaur-Knudsen; S. Mahil; T. Mälkönen; J. T. Maul; S. Mburu; U. Mrowietz; K. Reich; E. Remenyik; K. M. Rønholt; P. G. Sator; M. Schmitt-Egenolf; M. Sikora; K. Strömer; O. Sundnes; D. Trigos; G. van der Kraaij; N. Yawalkar; C. Dressler

doi:10.1111/jdv.16915

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations

A. Nast^*
, C. Smith
, P. I. Spuls
, G. Avila Valle
, Z. Bata-Csörgö
, H. Boonen
, E. de Jong
, I. Garcia-Doval
, P. Gisondi
, D. Kaur-Knudsen
, S. Mahil
, T. Mälkönen
, J. T. Maul
, S. Mburu
, U. Mrowietz
, K. Reich
, E. Remenyik
, K. M. Rønholt
, P. G. Sator
, M. Schmitt-Egenolf

M. Sikora, K. Strömer, O. Sundnes, D. Trigos, G. van der Kraaij, N. Yawalkar, C. Dressler

^*Corresponding author for this work

Charité – Universitätsmedizin Berlin
King's College London
Amsterdam UMC - University of Amsterdam
University of Szeged
Office-Based Dermatology Practice, Geel, Belgium
Radboud University Medical Center
Unidad de Investigación, Fundación Piel Sana AEDV, Madrid, España
University of Verona
University of Copenhagen
Guy's and St Thomas' NHS Foundation Trust
University of Helsinki
University Hospital Zürich
International Federation of Psoriasis Associations (IFPA)
Kiel University
University of Hamburg
University of Debrecen
Aarhus University
Municipal Hospital Hietzing, Vienna, Austria
Umeå University
Medical University of Warsaw
Office-Based Dermatology Practice, Mönchengladbach, Germany
University of Oslo
University of Bern

Research output: Contribution to journal › Article › Academic › peer-review

77 Downloads (Pure)

Abstract

This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The first part of the guideline includes general information on the scope and purpose, health questions covered, target users and strength/limitations of the guideline. Suggestions for disease severity grading and treatment goals are provided. It presents the general treatment recommendations as well as detailed management and monitoring recommendations for the individual drugs. The treatment options discussed in this guideline are as follows: acitretin, ciclosporin, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab.

Original language	English
Pages (from-to)	2461-2498
Number of pages	38
Journal	Journal of the European Academy of Dermatology and Venereology
Volume	34
Issue number	11
DOIs	https://doi.org/10.1111/jdv.16915
Publication status	Published - 1 Nov 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1111/jdv.16915

Euroguiderm-guideline-on-the-systemic-treatment-of-psoriasis-vulgaris--part-1-treatment-and-monitoring-recommendations.pdfFinal published version, 1.74 MB

Cite this

Nast, A., Smith, C., Spuls, P. I., Avila Valle, G., Bata-Csörgö, Z., Boonen, H., de Jong, E., Garcia-Doval, I., Gisondi, P., Kaur-Knudsen, D., Mahil, S., Mälkönen, T., Maul, J. T., Mburu, S., Mrowietz, U., Reich, K., Remenyik, E., Rønholt, K. M., Sator, P. G., ... Dressler, C. (2020). EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations. Journal of the European Academy of Dermatology and Venereology, 34(11), 2461-2498. https://doi.org/10.1111/jdv.16915

@article{008c06a5a7984145a5866f001359a750,

title = "EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations",

abstract = "This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The first part of the guideline includes general information on the scope and purpose, health questions covered, target users and strength/limitations of the guideline. Suggestions for disease severity grading and treatment goals are provided. It presents the general treatment recommendations as well as detailed management and monitoring recommendations for the individual drugs. The treatment options discussed in this guideline are as follows: acitretin, ciclosporin, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab.",

author = "A. Nast and C. Smith and Spuls, \{P. I.\} and \{Avila Valle\}, G. and Z. Bata-Cs{\"o}rg{\"o} and H. Boonen and \{de Jong\}, E. and I. Garcia-Doval and P. Gisondi and D. Kaur-Knudsen and S. Mahil and T. M{\"a}lk{\"o}nen and Maul, \{J. T.\} and S. Mburu and U. Mrowietz and K. Reich and E. Remenyik and R{\o}nholt, \{K. M.\} and Sator, \{P. G.\} and M. Schmitt-Egenolf and M. Sikora and K. Str{\"o}mer and O. Sundnes and D. Trigos and \{van der Kraaij\}, G. and N. Yawalkar and C. Dressler",

year = "2020",

month = nov,

day = "1",

doi = "10.1111/jdv.16915",

language = "English",

volume = "34",

pages = "2461--2498",

journal = "Journal of the European Academy of Dermatology and Venereology",

issn = "0926-9959",

publisher = "Wiley Blackwell",

number = "11",

}

Nast, A, Smith, C, Spuls, PI, Avila Valle, G, Bata-Csörgö, Z, Boonen, H, de Jong, E, Garcia-Doval, I, Gisondi, P, Kaur-Knudsen, D, Mahil, S, Mälkönen, T, Maul, JT, Mburu, S, Mrowietz, U, Reich, K, Remenyik, E, Rønholt, KM, Sator, PG, Schmitt-Egenolf, M, Sikora, M, Strömer, K, Sundnes, O, Trigos, D, van der Kraaij, G, Yawalkar, N & Dressler, C 2020, 'EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations', Journal of the European Academy of Dermatology and Venereology, vol. 34, no. 11, pp. 2461-2498. https://doi.org/10.1111/jdv.16915

TY - JOUR

T1 - EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations

AU - Nast, A.

AU - Smith, C.

AU - Spuls, P. I.

AU - Avila Valle, G.

AU - Bata-Csörgö, Z.

AU - Boonen, H.

AU - de Jong, E.

AU - Garcia-Doval, I.

AU - Gisondi, P.

AU - Kaur-Knudsen, D.

AU - Mahil, S.

AU - Mälkönen, T.

AU - Maul, J. T.

AU - Mburu, S.

AU - Mrowietz, U.

AU - Reich, K.

AU - Remenyik, E.

AU - Rønholt, K. M.

AU - Sator, P. G.

AU - Schmitt-Egenolf, M.

AU - Sikora, M.

AU - Strömer, K.

AU - Sundnes, O.

AU - Trigos, D.

AU - van der Kraaij, G.

AU - Yawalkar, N.

AU - Dressler, C.

PY - 2020/11/1

Y1 - 2020/11/1

N2 - This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The first part of the guideline includes general information on the scope and purpose, health questions covered, target users and strength/limitations of the guideline. Suggestions for disease severity grading and treatment goals are provided. It presents the general treatment recommendations as well as detailed management and monitoring recommendations for the individual drugs. The treatment options discussed in this guideline are as follows: acitretin, ciclosporin, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab.

AB - This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The first part of the guideline includes general information on the scope and purpose, health questions covered, target users and strength/limitations of the guideline. Suggestions for disease severity grading and treatment goals are provided. It presents the general treatment recommendations as well as detailed management and monitoring recommendations for the individual drugs. The treatment options discussed in this guideline are as follows: acitretin, ciclosporin, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab.

UR - https://www.scopus.com/pages/publications/85097922665

U2 - 10.1111/jdv.16915

DO - 10.1111/jdv.16915

M3 - Article

C2 - 33349983

SN - 0926-9959

VL - 34

SP - 2461

EP - 2498

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

IS - 11

ER -

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this